Advertisement

Back to the future: lessons from development drive innovation of human pluripotent stem cell therapies

  • Author Footnotes
    # A.D. and C.M.S. contributed equally to writing the meeting report.
    Andrea Ditadi
    Correspondence
    Offprint requests to Andrea Ditadi, San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Via Olgettina, 58, Milan, 20132, Italy
    Footnotes
    # A.D. and C.M.S. contributed equally to writing the meeting report.
    Affiliations
    San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
    Search for articles by this author
  • Author Footnotes
    # A.D. and C.M.S. contributed equally to writing the meeting report.
    Christopher M. Sturgeon
    Correspondence
    Offprint requests to Christopher M. Sturgeon, Icahn School of Medicine at Mount Sinai, Black Family Stem Cell Institute, One Gustave L. Levy Place, Box 1496, New York, NY 10029
    Footnotes
    # A.D. and C.M.S. contributed equally to writing the meeting report.
    Affiliations
    Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY

    Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai School of Medicine, New York, NY
    Search for articles by this author
  • Author Footnotes
    # A.D. and C.M.S. contributed equally to writing the meeting report.
Published:November 15, 2022DOI:https://doi.org/10.1016/j.exphem.2022.11.003

      Highlights

      • Leaders in hPSC-derived hematopoiesis met in Seattle, Washington, for a 1-day symposium.
      • hPSC-based blood disease modeling allows identification of new potential therapeutic targets.
      • hPSC-derived immune cells for “off-the-shelf” use display robust antitumor properties.
      • hPSC differentiation protocols recapitulating different ontogenies yield blood cells with distinct function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Experimental Hematology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Kaufman D, 2022. Available at: https://twitter.com/Kaufm020/status/1574200565210324992. Accessed November 29, 2022.

        • Kotini AG
        • Chang C-JJ
        • Chow A
        • et al.
        Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia.
        Cell Stem Cell. 2017; 20 (e7): 315-328
        • Lee J
        • Salci KR
        • Reid JC
        • et al.
        Brief report: human acute myeloid leukemia reprogramming to pluripotency is a rare event and selects for patient hematopoietic cells devoid of leukemic mutations.
        Stem Cells. 2017; 35: 2095-2102
        • Hsu J
        • Reilly A
        • Hayes BJ
        • et al.
        Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes.
        Blood. 2019; 134: 186-198
        • Doulatov S
        • Papapetrou EP.
        Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells.
        Curr Opin Hematol. 2021; 28: 50-56
        • Clough CA
        • Pangallo J
        • Sarchi M
        • et al.
        Coordinated mis-splicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome.
        Blood. 2021; 139: 2038-2049
        • Reilly A
        • Creamer JP
        • Stewart S
        • et al.
        Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function.
        Cell Stem Cell. 2022; 29 (e8): 577-592
        • Li Y
        • Hermanson DL
        • Moriarity BS
        • et al.
        Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity.
        Cell Stem Cell. 2018; 23 (e5): 181-192
        • Zhu H
        • Blum RH
        • Bjordahl R
        • et al.
        Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
        Blood. 2020; 135: 399-410
        • Pouyanfard S
        • Meshgin N
        • Cruz LS
        • et al.
        Human induced pluripotent stem cell-derived macrophages ameliorate liver fibrosis.
        Stem Cells. 2021; 39: 1701-1717
        • Brok-Volchanskaya VS
        • Bennin DA
        • Suknuntha K
        • et al.
        Effective and rapid generation of functional neutrophils from induced pluripotent stem cells using ETV2-modified mRNA.
        Stem Cell Rep. 2019; 13: 1099-1110
        • Vo LT
        • Kinney MA
        • Liu X
        • et al.
        Regulation of embryonic haematopoietic multipotency by EZH1.
        Nature. 2018; 553: 506
        • Jing R
        • Scarfo I
        • Najia MA
        • et al.
        EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.
        Cell Stem Cell. 2022; 29 (e6): 1181-1196
        • Themeli M
        • Kloss CC
        • Ciriello G
        • et al.
        Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.
        Nat Biotechnol. 2013; 31: 928
        • van der Stegen SJC
        • Lindenbergh PL
        • Petrovic RM
        • et al.
        Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.
        Nat Biomed Eng. 2022; 6: 1284-1297
        • Sturgeon CM
        • Ditadi A
        • Awong G
        • et al.
        Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells.
        Nat Biotechnol. 2014; 32: 554-561
        • Michaels YS
        • Edgar JM
        • Major MC
        • et al.
        DLL4 and VCAM1 enhance the emergence of T cell–competent hematopoietic progenitors from human pluripotent stem cells.
        Sci Adv. 2022; 8: eabn5522
        • Palis J.
        Hematopoietic stem cell-independent hematopoiesis: emergence of erythroid, megakaryocyte, and myeloid potential in the mammalian embryo.
        FEBS Lett. 2016; 590: 3965-3974
        • Dzierzak E
        • Bigas A.
        Blood development: hematopoietic stem cell dependence and independence.
        Cell Stem Cell. 2018; 22: 639-651
        • Ditadi A
        • Sturgeon CM
        • Keller G.
        A view of human haematopoietic development from the Petri dish.
        Nat Rev Mol Cell Biol. 2016; 18: 56-67
        • Kennedy M
        • Awong G
        • Sturgeon CM
        • et al.
        T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures.
        Cell Rep. 2012; 2: 1722-1735
        • Yang D
        • Gomez-Garcia J
        • Funakoshi S
        • et al.
        Modeling human multi-lineage heart field development with pluripotent stem cells.
        Cell Stem Cell. 2022; 29 (e8): 1382-1401
        • Protze SI
        • Liu J
        • Nussinovitch U
        • et al.
        Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker.
        Nat Biotechnol. 2017; 35: 56-68
        • Lee JH
        • Protze SI
        • Laksman Z
        • et al.
        Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations.
        Cell Stem Cell. 2017; 21 (e4): 179-194
        • Gage BK
        • Merlin S
        • Olgasi C
        • et al.
        Therapeutic correction of hemophilia A by transplantation of hPSC-derived liver sinusoidal endothelial cell progenitors.
        Cell Rep. 2022; 39110621
        • Atkins MH
        • Scarfò R
        • McGrath KE
        • et al.
        Modeling human yolk sac hematopoiesis with pluripotent stem cells.
        J Exp Med. 2021; 219e20211924
        • Dege C
        • Fegan KH
        • Creamer JP
        • et al.
        Potently cytotoxic natural killer cells initially emerge from erythro-myeloid progenitors during mammalian development.
        Dev Cell. 2020; 53 (e7): 229-239
        • Luff SA
        • Creamer JP
        • Valsoni S
        • et al.
        Identification of a retinoic acid-dependent haemogenic endothelial progenitor from human pluripotent stem cells.
        Nat Cell Biol. 2022; 24: 616-624
        • Calvanese V
        • Capellera-Garcia S
        • Ma F
        • et al.
        Mapping human haematopoietic stem cells from haemogenic endothelium to birth.
        Nature. 2022; 604: 534-540
        • Wilkinson AC
        • Igarashi KJ
        • Nakauchi H.
        Haematopoietic stem cell self-renewal in vivo and ex vivo.
        Nat Rev Genet. 2020; 21: 541-554
        • Dignum T
        • Varnum-Finney B
        • Srivatsan SR
        • et al.
        Multipotent progenitors and hematopoietic stem cells arise independently from hemogenic endothelium in the mouse embryo.
        Cell Rep. 2021; 36109675
        • Ditadi A
        • Sturgeon CM
        • Tober J
        • et al.
        Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages.
        Nat Cell Biol. 2015; 17: 580-591